The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) in 2018 demonstrated the value of an omega-3 fatty acid formulation, icosapent ethyl (eicosapentaenoic acid ethyl ester) for preventive treatment of atherosclerotic cardiovascular disease (ASCVD). This JCL Roundtable discussion brings together three experts to explore the origins and implications of REDUCE-IT and more broadly omega-3 fatty acids for mitigation of ASCVD risk. REDUCE-IT achieved a highly significant 25% reduction of major adverse cardiovascular events. It is the first trial of a triglyceride-lowering drug to gain unequivocal success in high-risk patients treated intensively with statins. It corroborates positive results from an earlier major trial using eicosapentaenoic acid (EPA) ethyl ester, the Japan EPA Lipid Intervention Study (JELIS), which included hypercholesterolemic subjects treated with low-dose statin mostly in primary prevention. Together these studies mark a new avenue for preventive treatment of ASCVD. Omega-3 fatty acids also show some promise, though less decisively, for reducing inflammation and cardiovascular mortality in a broader context.

二十烷醛乙基干预试验（REDUCE-IT）在2018年减少了心血管事件，证明了ω-3脂肪酸制剂二十碳五乙酯（二十碳五烯酸乙酯）在预防动脉粥样硬化性心血管疾病（ASCVD）方面的价值。这次JCL圆桌讨论会聚集了三位专家，以探讨REDUCE-IT的起源和意义以及更广泛的omega-3脂肪酸对缓解ASCVD风险的影响。REDUCE-IT大大降低了主要不良心血管事件的25％。这是降低甘油三酸酯药物的首次试验，该试验在接受他汀类药物强化治疗的高危患者中获得了明确的成功。它证实了早期使用二十碳五烯酸（EPA）乙酯进行的重大试验的积极结果，即日本EPA脂质干预研究（JELIS），其中包括接受低剂量他汀类药物治疗的高胆固醇血症受试者，主要用于一级预防。这些研究共同标志着ASCVD预防治疗的新途径。Omega-3脂肪酸在更广泛的背景下还具有一定的前景，尽管起着决定性的作用，但在减少炎症和心血管疾病的死亡率方面具有一定的前景。